| Autor: |
Rothenberg, Marc E., Roufosse, Florence, Faguer, Stanislas, Gleich, Gerald J., Steinfeld, Jonathan, Yancey, Steven W., Mavropoulou, Eleni, Kwon, Namhee, García, Gabriel Ricardo, Sosso, Adriana, Wehbe, Luis, Yañez, Anahí, Blockmans, Daniël, Roufosse, Florence, Antila, Martti Anton, Blanco, Daniela, Grava, Sergio, Lima, Marina Andrade, Francisco Pez, Andreia Luisa, Faguer, Stanislas, Hamidou, Mohamed A., Kahn, Jean-Emmanuel, Lefévre, Guillaume, Brockow, Knut, Kern, Peter M., Reiter, Andreas J., Walz, Bastian, Welte, Tobias, Pane, Fabrizio, Vannucchi, Alessandro M., Cerino-Javier, Ruth, Gazca-Aguilar, Alfredo, Hernández-Colín, Dante D., Valdéz-López, Héctor Glenn, Kupryś-Lipińska, Izabela R., Musial, Jacek, Prejzner, Witold, Mihaly, Eniko, Popov, Viola, Zdrenghea, Mihnea Tudor, Gritsaev, Sergey V., Ivanov, Vladimir, Tsyba, Nikolay, Alonso, Aránzazu, Cid Xutgla, Maria Cinta, Fox, Maria Laura, Delgado, Regina Garcia, Hernández Rivas, Jesús María, Santillana, Guillermo Sanz, González, Ana Isabel, Wardlaw, Andrew J., Akuthota, Praveen, Butterfield, Joseph H., Chupp, Geoffrey L., Cox, John B., Gleich, Gerald J., Jhaveri, Devi, Rothenberg, Marc E. |
| Zdroj: |
The Journal of Allergy and Clinical Immunology: In Practice; September 2022, Vol. 10 Issue: 9 p2367-2374.e3 |
| Abstrakt: |
Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
